Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Amgen Inc (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 109,312,464
  • Shares Outstanding, K 615,949
  • Annual Sales, $ 23,747 M
  • Annual Income, $ 8,394 M
  • 60-Month Beta 1.21
  • Price/Sales 4.73
  • Price/Cash Flow 10.09
  • Price/Book 9.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 3.45
  • Number of Estimates 10
  • High Estimate 3.63
  • Low Estimate 3.04
  • Prior Year 3.47
  • Growth Rate Est. (year over year) -0.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
176.85 +0.35%
on 04/18/19
196.87 -9.85%
on 04/05/19
-13.84 (-7.23%)
since 03/18/19
3-Month
176.85 +0.35%
on 04/18/19
203.95 -12.98%
on 01/23/19
-26.41 (-12.95%)
since 01/18/19
52-Week
165.22 +7.41%
on 05/04/18
210.19 -15.57%
on 09/27/18
+2.36 (+1.35%)
since 04/18/18

Most Recent Stories

More News
In Psoriasis, Use of the IL-17 Inhibitors, Novartis' Cosentyx and Eli Lilly's Taltz, are Neck and Neck, but the Former Still Holds a Significant First-to-Market Edge Amongst Rheumatologists for the Treatment of Psoriatic Arthritis, According to Data Recently Collected by Spherix Global Insights

Spherix Global Insights has been tracking the evolution of the US psoriatic arthritis (PsA) market on a quarterly basis since 2015 via the RealTime Dynamix(TM): Psoriatic Arthritis (US) report series....

NVS : 76.41 (-1.15%)
AMGN : 177.47 (-2.74%)
Can Q1 Earnings Lift Healthcare ETFs Higher?

With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.

VHT : 161.47 (+0.20%)
XLV : 85.92 (+0.16%)
MRK : 73.19 (-0.99%)
IYH : 181.00 (+0.17%)
FHLC : 41.65 (+0.14%)
ABBV : 77.57 (-0.53%)
GILD : 62.95 (-0.47%)
AMGN : 177.47 (-2.74%)
PFE : 39.38 (-1.25%)
UNH : 221.75 (+2.26%)
Can Q1 Earnings Lift Healthcare ETFs Higher?

With negative earnings revisions, the healthcare sector is expected to witness earnings growth of 1.8% in the first quarter, suggesting smooth trading for healthcare ETFs.

VHT : 161.47 (+0.20%)
XLV : 85.92 (+0.16%)
MRK : 73.19 (-0.99%)
IYH : 181.00 (+0.17%)
FHLC : 41.65 (+0.14%)
ABBV : 77.57 (-0.53%)
GILD : 62.95 (-0.47%)
AMGN : 177.47 (-2.74%)
PFE : 39.38 (-1.25%)
UNH : 221.75 (+2.26%)
Amgen Foundation Launches Amgen Biotech Experience In Tampa, Florida

The Amgen Foundation, together with the University of South Florida (USF), today announced the launch of the Amgen Biotech Experience (ABE) program in Tampa, Florida, as part of its long-standing science...

AMGN : 177.47 (-2.74%)
Amgen Inc Falls 2.54% on Heavy Volume: Watch For Potential Rebound

Amgen Inc (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $183.27 to a high of $188.13. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $187.97...

AMGN : 177.47 (-2.74%)
CDC Foundation, Amgen Announce Program to Increase Awareness and Knowledge of Cardiovascular Diseases Globally

According to the World Health Organization (WHO), cardiovascular disease (CVD) is the leading cause of death worldwide, responsible for nearly 18 million deaths in 2016 alone. More than three-quarters...

AMGN : 177.47 (-2.74%)
Radius Health (RDUS) Rallies 33.4% YTD on Robust Tymlos Sales

Radius Health's (RDUS) lead drug, Tymlos, gains traction in 2018. Let us see how the drug will fare in 2019 amid increasing competition.

RDUS : 21.43 (-3.47%)
LLY : 115.20 (-1.12%)
NVS : 76.41 (-1.15%)
AMGN : 177.47 (-2.74%)
EVENITY(TM) (romosozumab-aqqg) Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

Amgen (NASDAQ: AMGN) today announced that EVENITY(TM) (romosozumab-aqqg) is now available for shipment to wholesalers in the U.S. EVENITY was approved by the U.S. Food and Drug Administration (FDA) on...

AMGN : 177.47 (-2.74%)
The Zacks Analyst Blog Highlights: Bank of America, Amgen, NextEra, T-Mobile and S&P Global

The Zacks Analyst Blog Highlights: Bank of America, Amgen, NextEra, T-Mobile and S&P Global

TMUS : 73.75 (+1.78%)
BAC : 30.03 (unch)
SPGI : 217.20 (+0.84%)
AMGN : 177.47 (-2.74%)
NEE : 189.36 (-0.15%)
California Life Sciences Institute (CLSI) Names Winner of Bay Area BioGENEius Student Biotechnology Competition

California Life Sciences Institute (CLSI) today named Las Lomas High School 10th grader Melanie Quan of Alamo the winner of the 2019 Amgen Bay Area BioGENEius Challenge, the premier...

AMGN : 177.47 (-2.74%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade AMGN with:

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Key Turning Points

2nd Resistance Point 185.91
1st Resistance Point 181.69
Last Price 177.47
1st Support Level 175.05
2nd Support Level 172.63

See More

52-Week High 210.19
Fibonacci 61.8% 193.01
Fibonacci 50% 187.71
Fibonacci 38.2% 182.40
Last Price 177.47
52-Week Low 165.22

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar